KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Adaptive Biotechnologies (ADPT) Receivables - Net (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Receivables - Net for 8 consecutive years, with $50.4 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 20.69% to $50.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.4 million through Dec 2025, up 20.69% year-over-year, with the annual reading at $50.4 million for FY2025, 20.69% up from the prior year.
  • Receivables - Net hit $50.4 million in Q4 2025 for Adaptive Biotechnologies, up from $44.8 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $50.4 million in Q4 2025 to a low of $14.2 million in Q2 2021.
  • Historically, Receivables - Net has averaged $32.8 million across 5 years, with a median of $33.6 million in 2023.
  • Biggest five-year swings in Receivables - Net: skyrocketed 130.09% in 2022 and later fell 5.21% in 2023.
  • Year by year, Receivables - Net stood at $17.4 million in 2021, then surged by 130.09% to $40.1 million in 2022, then dropped by 5.21% to $38.0 million in 2023, then increased by 9.91% to $41.7 million in 2024, then increased by 20.69% to $50.4 million in 2025.
  • Business Quant data shows Receivables - Net for ADPT at $50.4 million in Q4 2025, $44.8 million in Q3 2025, and $44.3 million in Q2 2025.